GSK•benzinga•April 7, 2025 at 11:37 AM

ABL Bio Announced A Worldwide Licensing Agreement With GSK To Develop Medicines For Neurodegenerative Diseases By Utilizing ABL Bio's Blood-brain Barrier Shuttle Platform, Grabody-B, ABL Bio Will Receive Up To £2.075B Including £77.1M In Upfront And Near-

No summary available.

Read the full article from the original source for complete details and context.

Article published on April 7, 2025 by benzinga